Chemotherapy-induced Necrosis in Ewing Sarcoma

Completed

• Conditions: Ewing Sarcoma of Bone

• Registration Number: NCT03968471
• Lead Sponsor: Istituto Ortopedico Rizzoli

Brief Summary

This is single institution cases series review of histological and clinical data

Detailed Description

Investigators will retrieve from the database of the Rizzoli institute all the cases with a histological diagnosis of Ewing sarcoma from 01 Jan 1982 to 31 Dic 2012

Study Timeline

• Study Start: 2019-05-13
• Study First Submitted: 2019-05-24
• Study First Submitted QC: 2019-05-29
• Study First Posted: 2019-05-30
• Primary Completion: 2019-12-31
• Status Verified: 2020-01
• Study Completion: 2020-01-15
• Last Update Submitted: 2020-01-21
• Last Update Posted: 2020-01-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 474

Inclusion Criteria

1. Male and female patients surgically treated at Rizzoli Institute from 01 Jan 1982 to 31 Dic 2012
2. Patients with diagnosis of Ewing sarcoma of bone who have had neo-adjuvant chemotherapy
3. Diagnosis of Ewing sarcoma localized

Exclusion Criteria

1. Metastatic disease at presentation
2. Soft tissue origin
3. Radiotherapy before surgery

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
retrospective analysis of cases of Ewing sarcomas	at baseline (Day0)	Investigators will exam the histological response to chemotherapy in localized Ewing sarcoma of bone and correlate it to clinical outcome.

Trial Locations

Locations (1)

Dept. of Pathology of IRCCS Istituto Ortopedico Rizzoli; 🇮🇹 Bologna, Italy